SCHEMBL4308926

SCHEMBL4308926

Nc1cccc2c1C(=O)N(c1ccc(F)cc1/C=C/c1n[nH]c3ccccc13)C2=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ XBP1 P17861 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ HSPA1A P0DMV8 1/20 0.38
▸ PABPC1 P11940 1/20 0.38
▸ CHEK1 O14757 6/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ CDK4 P11802 4/20 0.35
▸ KDR P35968 4/20 0.35
▸ CSF1R P07333 2/20 0.35
▸ PDGFRB P09619 2/20 0.35
▸ KIT P10721 2/20 0.35
▸ PDGFRA P16234 2/20 0.35
▸ AURKA O14965 2/20 0.35
▸ AURKB Q96GD4 2/20 0.35
▸ BMPR1B O00238 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4308931 1.00 KDM4E (0.38) KDM4EALDH1A1MAPTMEN1XBP1
SCHEMBL4309384 0.90 CHEK1 (0.43) KDM4EALDH1A1MAPTCHEK1CDK4
SCHEMBL4309378 0.90 CHEK1 (0.43) KDM4EALDH1A1MAPTCHEK1CDK4
SCHEMBL4319846 0.88 NR1H3 (0.43) HSPA1APABPC1CHEK1POLBCDK4
SCHEMBL4319841 0.88 NR1H3 (0.43) HSPA1APABPC1CHEK1POLBCDK4
SCHEMBL4315455 0.87 LMNA (0.45) KDM4EALDH1A1MEN1XBP1KMT2A
SCHEMBL4315461 0.87 LMNA (0.45) KDM4EALDH1A1MEN1XBP1KMT2A
SCHEMBL4310272 0.83 KDR (0.38) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL4310281 0.83 KDR (0.38) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL4311434 0.81 ALPL (0.45) CHEK1CDK4CCNA2CCND1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 — — US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 — — US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 KDM4E 1251/4885ALDH1A1 1250/4885MAPT 4175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback